首页> 外文期刊>Current treatment options in cardiovascular medicine >Injectable Bioengineered Hydrogel Therapy in the Treatment of Ischemic Cardiomyopathy
【24h】

Injectable Bioengineered Hydrogel Therapy in the Treatment of Ischemic Cardiomyopathy

机译:可注射生物工程水凝胶疗法治疗缺血性心肌病

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Over the past two decades, the field of cardiovascular medicine has seen the rapid development of multiple different modalities for the treatment of ischemic myocardial disease. Most research efforts have focused on strategies aimed at coronary revasculari-zation, with significant technological advances made in percutaneous coronary interventions as well as coronary artery bypass graft surgery. However, recent research efforts have shifted towards ways to address the downstream effects of myocardial infarction on both cellular and molecular levels. To this end, the broad application of injectable hydrogel therapy after myocardial infarction has stimulated tremendous interest. In this article, we will review what hydrogels are, how they can be bioengineered in unique ways to optimize therapeutic potential, and how they can be used as part of a treatment strategy after myocardial infarction.
机译:在过去的二十年中,心血管医学领域已经看出了多种不同方式的缺血性心肌疾病的快速发展。 大多数研究努力侧重于旨在冠状动脉血管型Zation的策略,具有经皮冠状动脉干预的重要技术进步以及冠状动脉旁路移植手术。 然而,最近的研究努力转向了解决心肌梗塞对细胞和分子水平的下游效果的方式。 为此,心肌梗死后可注射水凝胶治疗的广泛应用刺激了巨大的兴趣。 在本文中,我们将审查水凝胶是什么,如何以独特的方式生物工程,以优化治疗潜力,以及如何在心肌梗死后作为治疗策略的一部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号